{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:26:31Z","timestamp":1792499191910,"version":"4.5.0"},"reference-count":109,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T00:00:00Z","timestamp":1701475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000072","name":"National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Denosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This document seeks to summarize the evidence and provide expert opinion on safe and appropriate use of denosumab in pediatric RANKL-mediated disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Ten experts in pediatric bone and mineral medicine from 6 countries with experience in the use of denosumab participated in the creation of this document.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Evidence<\/jats:title>\n                    <jats:p>Data were sourced from the published literature, primarily consisting of case reports\/series and review articles because of the lack of higher level evidence. Expert opinion of the authors was used substantially when no published data were available.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and, in some cases, is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimize risks.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad657","type":"journal-article","created":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T01:24:30Z","timestamp":1701307470000},"page":"1371-1382","source":"Crossref","is-referenced-by-count":28,"title":["Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document"],"prefix":"10.1210","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7063-6667","authenticated-orcid":false,"given":"Joel A","family":"Vanderniet","sequence":"first","affiliation":[{"name":"Sydney Medical School, Faculty of Medicine and Health, The University of Sydney and Institute of Endocrinology and Diabetes, The Children\u2019s Hospital at Westmead , Sydney, NSW 2145 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Szymczuk","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda, MD 20814 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6304","authenticated-orcid":false,"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University Linz , Linz 4020 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe S","family":"Beck-Nielsen","sequence":"additional","affiliation":[{"name":"Centre for Rare Diseases, Aarhus University Hospital and Department of Clinical Medicine, Aarhus University , Aarhus N DK-8200 , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma","family":"Uday","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes, Birmingham Women's and Children's Hospital and Institute of Metabolism and Systems Research, University of Birmingham , Birmingham B15 2TG , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Merchant","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, Children's National Hospital , Washington, DC 20010 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet L","family":"Crane","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Department of Orthopedic Surgery, Johns Hopkins University , Baltimore, MD 21287 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-9185","authenticated-orcid":false,"given":"Leanne M","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Ottawa and Division of Endocrinology, Children's Hospital of Eastern Ontario , Ottawa, Ontario K1H 8L1 , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M","family":"Boyce","sequence":"additional","affiliation":[{"name":"Metabolic Bone Disorders Unit, National Institute of Dental and Craniofacial Research, National Institutes of Health , Bethesda, MD 20814 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig F","family":"Munns","sequence":"additional","affiliation":[{"name":"Child Health Research Centre and Mayne Academy of Paediatrics, University of Queensland , Brisbane, QLD 4101 , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,12,2]]},"reference":[{"issue":"10","key":"2024041923070376500_dgad657-B1","first-page":"1","article-title":"Denosumab 60 mg (Prolia): should not be used in patients under 18 years due to the risk of serious hypercalcaemia","volume":"15","author":"United Kingdom Medicines and Healthcare Products Regulatory Agency","year":"2022","journal-title":"Drug Saf Update"},{"issue":"2","key":"2024041923070376500_dgad657-B2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11914-021-00657-z","article-title":"Denosumab treatment for giant cell tumors, aneurysmal bone cysts, and fibrous dysplasia-risks and benefits","volume":"19","author":"Pan","year":"2021","journal-title":"Curr Osteoporos Rep"},{"issue":"4","key":"2024041923070376500_dgad657-B3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.path.2021.06.010","article-title":"Giant cell-rich tumors of bone","volume":"14","author":"Hartmann","year":"2021","journal-title":"Surg Pathol Clin"},{"issue":"1","key":"2024041923070376500_dgad657-B4","first-page":"297","article-title":"The histogenesis of giant cell tumour of bone: a model of interaction between neoplastic cells and osteoclasts","volume":"16","author":"Zheng","year":"2001","journal-title":"Histol Histopathol"},{"issue":"5","key":"2024041923070376500_dgad657-B5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.tripleo.2007.04.003","article-title":"Central giant cell granuloma of the jaw: a review of the literature with emphasis on therapy options","volume":"104","author":"de Lange","year":"2007","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"2024041923070376500_dgad657-B6","first-page":"365","article-title":"Aneurysmal bone cyst of the pelvis and extremities: contemporary management","volume":"4","author":"Noordin","year":"2019","journal-title":"Int J Surg Oncol"},{"issue":"2","key":"2024041923070376500_dgad657-B7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0030-4220(88)90094-1","article-title":"A clinical and histomorphologic comparison of the central giant cell granuloma and the giant cell tumor","volume":"66","author":"Auclair","year":"1988","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"1","key":"2024041923070376500_dgad657-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2013.03.005","article-title":"USP6-induced neoplasms: the biologic spectrum of aneurysmal bone cyst and nodular fasciitis","volume":"45","author":"Oliveira","year":"2014","journal-title":"Hum Pathol"},{"issue":"9","key":"2024041923070376500_dgad657-B9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"2024041923070376500_dgad657-B10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00586-013-2715-7","article-title":"Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts","volume":"22","author":"Lange","year":"2013","journal-title":"Eur Spine J"},{"issue":"8","key":"2024041923070376500_dgad657-B11","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/jop.12730","article-title":"Central giant cell lesion of the jaws: an updated analysis of 2270 cases reported in the literature","volume":"47","author":"Chrcanovic","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"4","key":"2024041923070376500_dgad657-B12","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s00586-018-5470-y","article-title":"Bisphosphonate therapy for spinal aneurysmal bone cysts","volume":"27","author":"Kieser","year":"2018","journal-title":"Eur Spine J"},{"key":"2024041923070376500_dgad657-B13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2013.10.004","article-title":"Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy","volume":"58","author":"Cornelis","year":"2014","journal-title":"Bone"},{"issue":"5","key":"2024041923070376500_dgad657-B14","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1097\/BPO.0b013e318285c3a7","article-title":"Successful treatment of a sacral aneurysmal bone cyst with zoledronic acid","volume":"33","author":"Simm","year":"2013","journal-title":"J Pediatr Orthop"},{"key":"2024041923070376500_dgad657-B15","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.jbo.2022.100441","article-title":"Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: a randomized clinical trial","volume":"35","author":"Yue","year":"2022","journal-title":"J Bone Oncol"},{"issue":"5","key":"2024041923070376500_dgad657-B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11912-021-01047-5","article-title":"Giant cell tumor of bone: an update","volume":"23","author":"Mallick","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"2024041923070376500_dgad657-B17","doi-asserted-by":"crossref","first-page":"e399","DOI":"10.1097\/MPH.0000000000000380","article-title":"Zoledronic acid for the treatment of children with refractory central giant cell granuloma","volume":"37","author":"Chien","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"2024041923070376500_dgad657-B18","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/00000478-200305000-00003","article-title":"Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations","volume":"27","author":"Dehner","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"(Suppl 3)","key":"2024041923070376500_dgad657-B19","doi-asserted-by":"crossref","first-page":"S555","DOI":"10.1007\/s00586-018-5651-8","article-title":"Solitary juvenile xanthogranuloma in the spine pretreated with neoadjuvant denosumab therapy followed by surgical resection in a 5-year-old child: case report and literature review","volume":"27","author":"Irmola","year":"2018","journal-title":"Eur Spine J"},{"issue":"(Suppl 2)","key":"2024041923070376500_dgad657-B20","doi-asserted-by":"crossref","first-page":"S318","DOI":"10.1007\/s00586-008-0606-0","article-title":"Solitary juvenile xanthogranuloma in the upper cervical spine: case report and review of the literatures","volume":"17","author":"Cao","year":"2008","journal-title":"Eur Spine J"},{"issue":"2","key":"2024041923070376500_dgad657-B21","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0022-3476(96)70247-0","article-title":"Juvenile xanthogranuloma: forms of systemic disease and their clinical implications","volume":"129","author":"Freyer","year":"1996","journal-title":"J Pediatr"},{"issue":"24","key":"2024041923070376500_dgad657-B22","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM199112123252403","article-title":"Activating mutations of the stimulatory G protein in the McCune-Albright syndrome","volume":"325","author":"Weinstein","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"2024041923070376500_dgad657-B23","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s13244-018-0666-6","article-title":"Fibrous dysplasia for radiologists: beyond ground glass bone matrix","volume":"9","author":"Kushchayeva","year":"2018","journal-title":"Insights Imaging"},{"issue":"2","key":"2024041923070376500_dgad657-B24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/(SICI)1096-9896(199901)187:2<249::AID-PATH222>3.0.CO;2-J","article-title":"The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs? gene: site-specific patterns and recurrent histological hallmarks","volume":"187","author":"Riminucci","year":"1999","journal-title":"J Pathol"},{"issue":"2","key":"2024041923070376500_dgad657-B25","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024041923070376500_dgad657-B26","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL Inhibition in fibrous dysplasia of bone: a preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2024041923070376500_dgad657-B27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMc2214862","article-title":"Safety and efficacy of denosumab for fibrous dysplasia of bone","volume":"388","author":"de Castro","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"2024041923070376500_dgad657-B28","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/odi.12563","article-title":"Fibrous dysplasia of bone: craniofacial and dental implications","volume":"23","author":"Burke","year":"2017","journal-title":"Oral Dis"},{"issue":"Suppl 1","key":"2024041923070376500_dgad657-B29","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1750-1172-7-S1-S1","article-title":"The surgical management of fibrous dysplasia of bone","volume":"7","author":"Stanton","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2024041923070376500_dgad657-B30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2024041923070376500_dgad657-B31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024041923070376500_dgad657-B32","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1210\/jc.2018-02543","article-title":"Denosumab in patients with fibrous dysplasia previously treated with bisphosphonates","volume":"104","author":"Majoor","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024041923070376500_dgad657-B33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1056\/NEJMoa013096","article-title":"Osteoprotegerin deficiency and juvenile Paget's Disease","volume":"347","author":"Whyte","year":"2002","journal-title":"N Engl J Med"},{"key":"2024041923070376500_dgad657-B34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.metabol.2017.10.007","article-title":"Juvenile Paget disease","volume":"80","author":"Polyzos","year":"2018","journal-title":"Metab Clin Exp"},{"key":"2024041923070376500_dgad657-B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bone.2014.07.019","article-title":"Juvenile Paget's Disease with heterozygous duplication within TNFRSF11A encoding RANK","volume":"68","author":"Whyte","year":"2014","journal-title":"Bone"},{"issue":"1","key":"2024041923070376500_dgad657-B36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.berh.2007.11.005","article-title":"Juvenile Paget's Disease, familial expansile osteolysis and other genetic osteolytic disorders","volume":"22","author":"Ralston","year":"2008","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"9","key":"2024041923070376500_dgad657-B37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1056\/NEJMoa050893","article-title":"Recombinant osteoprotegerin for juvenile Paget's Disease","volume":"353","author":"Cundy","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"2024041923070376500_dgad657-B38","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024041923070376500_dgad657-B39","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"2024041923070376500_dgad657-B40","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: an emerging therapy in pediatric bone disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"2024041923070376500_dgad657-B41","first-page":"e3989","article-title":"Denosumab therapy in the management of aneurysmal bone cysts: a comprehensive literature review","volume":"11","author":"Alhumaid","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"2024041923070376500_dgad657-B42","doi-asserted-by":"crossref","first-page":"105260","DOI":"10.1016\/j.jbspin.2021.105260","article-title":"Denosumab in the management of aneurysmal bone cyst: a literature review","volume":"89","author":"Maximen","year":"2022","journal-title":"Joint Bone Spine"},{"key":"2024041923070376500_dgad657-B43","doi-asserted-by":"crossref","first-page":"101687","DOI":"10.1016\/j.bonr.2023.101687","article-title":"Giant cell tumour of bone in os sacrum of a prepubertal girl\u2014surgical and medical treatment with zoledronate and denosumab","volume":"18","author":"Beck-Nielsen","year":"2023","journal-title":"Bone Rep"},{"issue":"5","key":"2024041923070376500_dgad657-B44","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00223-023-01068-1","article-title":"Surgical management and denosumab for aneurysmal bone cysts of the spine in an Australian tertiary paediatric centre","volume":"112","author":"Vanderniet","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"2024041923070376500_dgad657-B45","doi-asserted-by":"crossref","first-page":"116395","DOI":"10.1016\/j.bone.2022.116395","article-title":"Denosumab for central giant cell granuloma in an Australian tertiary paediatric centre","volume":"159","author":"Vanderniet","year":"2022","journal-title":"Bone"},{"issue":"3","key":"2024041923070376500_dgad657-B46","doi-asserted-by":"crossref","first-page":"e28778","DOI":"10.1002\/pbc.28778","article-title":"Treatment of central giant cell granuloma in children with denosumab","volume":"68","author":"Choe","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2024041923070376500_dgad657-B47","doi-asserted-by":"crossref","first-page":"698963","DOI":"10.3389\/fendo.2021.698963","article-title":"Mineral and bone consequences of high dose denosumab therapy to treat an aneurysmal bone cyst, a child case report","volume":"12","author":"Del Sindaco","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2024041923070376500_dgad657-B48","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s00198-021-05895-6","article-title":"Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects","volume":"32","author":"Raborn","year":"2021","journal-title":"Osteoporos Int"},{"key":"2024041923070376500_dgad657-B49","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3389\/fped.2020.00515","article-title":"Case report: safety and efficacy of denosumab in four children with noonan syndrome with multiple giant cell lesions of the jaw","volume":"8","author":"Ferriero","year":"2020","journal-title":"Front Pediatr"},{"issue":"5","key":"2024041923070376500_dgad657-B50","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s12519-020-00378-w","article-title":"Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?","volume":"16","author":"Sydlik","year":"2020","journal-title":"World J Pediatr"},{"key":"2024041923070376500_dgad657-B51","first-page":"8854441","article-title":"The efficacy of denosumab in the management of a tibial paediatric aneurysmal bone cyst compromised by rebound hypercalcaemia","volume":"2020","author":"Harcus","year":"2020","journal-title":"Case Rep Pediatr"},{"issue":"9","key":"2024041923070376500_dgad657-B52","doi-asserted-by":"crossref","first-page":"e10196","DOI":"10.1002\/jbm4.10196","article-title":"Local tumor recurrence and escape from suppression of bone resorption with denosumab treatment in two adolescents with giant cell tumors of bone","volume":"3","author":"Akel","year":"2019","journal-title":"JBMR Plus"},{"issue":"1","key":"2024041923070376500_dgad657-B53","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s12891-019-2855-y","article-title":"Aneurysmal bone cyst: results of an off label treatment with denosumab","volume":"20","author":"Durr","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"2024041923070376500_dgad657-B54","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.otsr.2019.04.028","article-title":"Denosumab for treating aneurysmal bone cysts in children","volume":"105","author":"Raux","year":"2019","journal-title":"Orthop Traumatol Surg Res"},{"issue":"10","key":"2024041923070376500_dgad657-B55","doi-asserted-by":"crossref","first-page":"e10210","DOI":"10.1002\/jbm4.10210","article-title":"Use of denosumab in children with osteoclast bone dysplasias: report of three cases","volume":"3","author":"Upfill-Brown","year":"2019","journal-title":"JBMR Plus"},{"issue":"4","key":"2024041923070376500_dgad657-B56","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.joms.2017.09.013","article-title":"Denosumab as a treatment alternative for central giant cell granuloma: a long-term retrospective cohort study","volume":"76","author":"Bredell","year":"2018","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"2024041923070376500_dgad657-B57","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1210\/jc.2017-02025","article-title":"Osteonecrosis of the jaw and rebound hypercalcemia in young people treated with denosumab for giant cell tumor of bone","volume":"103","author":"Uday","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2024041923070376500_dgad657-B58","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1177\/0300891618784808","article-title":"Denosumab in patients with aneurysmal bone cysts: a case series with preliminary results","volume":"104","author":"Palmerini","year":"2018","journal-title":"Tumori"},{"issue":"4","key":"2024041923070376500_dgad657-B59","doi-asserted-by":"crossref","first-page":"e26926","DOI":"10.1002\/pbc.26926","article-title":"Denosumab treatment in aneurysmal bone cyst: evaluation of nine cases","volume":"65","author":"Kurucu","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2024041923070376500_dgad657-B60","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/jbm4.10010","article-title":"Improvement of giant cell lesions of the jaw treated with high and low doses of denosumab: a case series","volume":"1","author":"Kim","year":"2017","journal-title":"JBMR Plus"},{"issue":"1","key":"2024041923070376500_dgad657-B61","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13052-017-0353-0","article-title":"Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female\u2014a case report and literature review","volume":"43","author":"Bardakhchyan","year":"2017","journal-title":"Ital J Pediatr"},{"issue":"1","key":"2024041923070376500_dgad657-B62","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"2024041923070376500_dgad657-B63","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/pbc.25393","article-title":"Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone","volume":"62","author":"Gossai","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"2024041923070376500_dgad657-B64","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/j.joms.2014.06.456","article-title":"Management of central giant cell granuloma with subcutaneous denosumab therapy","volume":"72","author":"Naidu","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"issue":"9967","key":"2024041923070376500_dgad657-B65","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0140-6736(14)61338-6","article-title":"Osteosclerosis induced by denosumab","volume":"385","author":"Kobayashi","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"2024041923070376500_dgad657-B66","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1200\/JCO.2012.46.4255","article-title":"Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl","volume":"31","author":"Karras","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"2024041923070376500_dgad657-B67","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1210\/jc.2013-1143","article-title":"Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's Disease","volume":"98","author":"Grasemann","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2024041923070376500_dgad657-B68","doi-asserted-by":"crossref","first-page":"100384","DOI":"10.1016\/j.jbo.2021.100384","article-title":"Current strategies for the treatment of solitary and aneurysmal bone cysts: a review of the literature","volume":"30","author":"Deventer","year":"2021","journal-title":"J Bone Oncol"},{"issue":"1","key":"2024041923070376500_dgad657-B69","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00590-021-03168-w","article-title":"Comparing clinical outcomes between extended curettage and wide resection in Enneking stage 3 giant cell tumor of bone","volume":"33","author":"Tuntarattanapong","year":"2023","journal-title":"Eur J Orthop Surg Traumatol"},{"issue":"4","key":"2024041923070376500_dgad657-B70","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CCO.0000000000000529","article-title":"Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone","volume":"31","author":"Lipplaa","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"2024041923070376500_dgad657-B71","doi-asserted-by":"crossref","first-page":"100417","DOI":"10.1016\/j.jbo.2022.100417","article-title":"Giant cell tumor of bone: a single center study of 115 cases","volume":"33","author":"Deventer","year":"2022","journal-title":"J Bone Oncol"},{"issue":"5","key":"2024041923070376500_dgad657-B72","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/CORR.0000000000001074","article-title":"Is treatment with denosumab associated with local recurrence in patients with giant cell tumor of bone treated with curettage? A systematic review","volume":"478","author":"Tsukamoto","year":"2020","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"2024041923070376500_dgad657-B73","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3171\/2022.8.PEDS22314","article-title":"The role of neoadjuvant denosumab in the treatment of aneurysmal bone cysts: a case series and review of the literature","volume":"30","author":"Giantini-Larsen","year":"2022","journal-title":"J Neurosurg Pediatr"},{"issue":"1","key":"2024041923070376500_dgad657-B74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40618-021-01630-4","article-title":"Mechanisms of acute hypercalcemia in pediatric patients following the interruption of denosumab","volume":"45","author":"Deodati","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2024041923070376500_dgad657-B75","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/scd.12588","article-title":"Successful denosumab treatment for central giant cell granuloma in a 9-year-old child","volume":"41","author":"Mariz","year":"2021","journal-title":"Spec Care Dentist"},{"issue":"7","key":"2024041923070376500_dgad657-B76","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1515\/jpem-2019-0581","article-title":"Efficacy and safety of denosumab treatment in a prepubertal patient with cherubism","volume":"33","author":"Kawamura","year":"2020","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2024041923070376500_dgad657-B77","first-page":"76","article-title":"Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"7","key":"2024041923070376500_dgad657-B78","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2024041923070376500_dgad657-B79"},{"issue":"5","key":"2024041923070376500_dgad657-B80","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","article-title":"Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics","volume":"27","author":"Popp","year":"2016","journal-title":"Osteoporos Int"},{"issue":"5","key":"2024041923070376500_dgad657-B81","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","article-title":"Observations following discontinuation of long-term denosumab therapy","volume":"28","author":"McClung","year":"2017","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024041923070376500_dgad657-B82","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2024041923070376500_dgad657-B83","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00198-017-4242-6","article-title":"Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study","volume":"29","author":"Zanchetta","year":"2018","journal-title":"Osteoporos Int"},{"issue":"11","key":"2024041923070376500_dgad657-B84","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024041923070376500_dgad657-B85","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1530\/EJE-16-1027","article-title":"Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment","volume":"176","author":"Anastasilakis","year":"2017","journal-title":"Eur J Endocrinol"},{"key":"2024041923070376500_dgad657-B86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"issue":"1","key":"2024041923070376500_dgad657-B87","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/jcm10010152","article-title":"Denosumab discontinuation and the rebound phenomenon: a narrative review","volume":"10","author":"Anastasilakis","year":"2021","journal-title":"J Clin Med"},{"issue":"5","key":"2024041923070376500_dgad657-B88","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00198-016-3553-3","article-title":"Cancel the denosumab holiday","volume":"27","author":"McClung","year":"2016","journal-title":"Osteoporos Int"},{"issue":"6","key":"2024041923070376500_dgad657-B89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11914-022-00756-5","article-title":"Osteoclast recycling and the rebound phenomenon following denosumab discontinuation","volume":"20","author":"Kim","year":"2022","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"2024041923070376500_dgad657-B90","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00223-012-9600-y","article-title":"Osteoclast fusion and fission","volume":"90","author":"Jansen","year":"2012","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2024041923070376500_dgad657-B91","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","article-title":"Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption","volume":"184","author":"McDonald","year":"2021","journal-title":"Cell"},{"key":"2024041923070376500_dgad657-B92","doi-asserted-by":"crossref","first-page":"101148","DOI":"10.1016\/j.bonr.2021.101148","article-title":"Hypercalcemia following discontinuation of denosumab therapy: a systematic review","volume":"15","author":"Horiuchi","year":"2021","journal-title":"Bone Rep"},{"issue":"5","key":"2024041923070376500_dgad657-B93","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00223-023-01065-4","article-title":"Mitigating the denosumab-induced rebound phenomenon with alternating short- and long-acting anti-resorptive therapy in a young boy with severe OI type VI","volume":"112","author":"Seale","year":"2023","journal-title":"Calcif Tissue Int"},{"issue":"8","key":"2024041923070376500_dgad657-B94","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJMe068003","article-title":"The long and the short of bone therapy","volume":"354","author":"Whyte","year":"2006","journal-title":"N Engl J Med"},{"issue":"10397","key":"2024041923070376500_dgad657-B95","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/S0140-6736(23)00915-7","article-title":"Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab","volume":"402","author":"Szymczuk","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"2024041923070376500_dgad657-B96","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"27","key":"2024041923070376500_dgad657-B97","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1056\/NEJMra040952","article-title":"Osteopetrosis","volume":"351","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"2024041923070376500_dgad657-B98","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1210\/jc.2017-01127","article-title":"Diagnosis and management of osteopetrosis: consensus guidelines from the osteopetrosis working group","volume":"102","author":"Wu","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2024041923070376500_dgad657-B99","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1600-0722.2008.00529.x","article-title":"Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta","volume":"116","author":"Kamoun-Goldrat","year":"2008","journal-title":"Eur J Oral Sci"},{"issue":"2","key":"2024041923070376500_dgad657-B100","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00223-020-00707-1","article-title":"Bisphosphonate therapy and tooth development in children and adolescents with osteogenesis imperfecta","volume":"107","author":"Malmgren","year":"2020","journal-title":"Calcif Tissue Int"},{"issue":"5","key":"2024041923070376500_dgad657-B101","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"issue":"9","key":"2024041923070376500_dgad657-B102","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00256-020-03449-1","article-title":"Radiological findings of denosumab treatment for giant cell tumours of bone","volume":"49","author":"van Langevelde","year":"2020","journal-title":"Skeletal Radiol"},{"issue":"6","key":"2024041923070376500_dgad657-B103","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/1754-9485.12249","article-title":"Magnetic resonance imaging aspects of giant-cell tumours of bone","volume":"58","author":"Pereira","year":"2014","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"supplement 1","key":"2024041923070376500_dgad657-B104","first-page":"S1279","article-title":"18F-FDG PET\/CT imaging in evaluation the efficacy of denosumab for giant cell tumor of bone","volume":"60","author":"Hao","year":"2019","journal-title":"J Nucl Med"},{"issue":"1","key":"2024041923070376500_dgad657-B105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12957-018-1478-3","article-title":"Assessment of denosumab treatment effects and imaging response in patients with giant cell tumor of bone","volume":"16","author":"Engellau","year":"2018","journal-title":"World J Surg Oncol"},{"issue":"1","key":"2024041923070376500_dgad657-B106","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jos.2020.11.005","article-title":"Clinical and pathological analysis of giant cell tumor of bone with denosumab treatment and local recurrence","volume":"27","author":"Hayashida","year":"2022","journal-title":"J Orthop Sci"},{"issue":"9","key":"2024041923070376500_dgad657-B107","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1002\/jbmr.3738","article-title":"(18) F-NaF PET\/CT imaging in fibrous dysplasia of bone","volume":"34","author":"Papadakis","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"9902","key":"2024041923070376500_dgad657-B108","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S0140-6736(13)61091-0","article-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"Bishop","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"2024041923070376500_dgad657-B109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad657\/54400190\/dgad657.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad657\/57285807\/dgad657.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad657\/57285807\/dgad657.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T19:09:06Z","timestamp":1713553746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/109\/5\/1371\/7458108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,2]]},"references-count":109,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,12,2]]},"published-print":{"date-parts":[[2024,4,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad657","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5]]},"published":{"date-parts":[[2023,12,2]]}}}